FORT-1: Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1 / 3 mRNA expression

Cora N. Sternberg, Daniel P. Petrylak, Joaquim Bellmunt, Hiroyuki Nishiyama, Andrea Necchi, Howard Gurney, Jae-Lyun Lee, Michiel S. Van Der Heijden, Eli Rosenbaum, Nicolas Penel, See-Tong Pang, Jian-Ri Li, Xavier García Del Muro, Florence Joly, Zsuzsanna Pápai, Weichao Bao, Peter Ellinghaus, Chengxing Lu, Mitchell Sierecki, Sabine CoppietersKeiko Nakajima, Tatiane Cristine Ishida, David I. Quinn*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

46 Citations (Scopus)
75 Downloads (Pure)

Fingerprint

Dive into the research topics of 'FORT-1: Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1 / 3 mRNA expression'. Together they form a unique fingerprint.

Medicine & Life Sciences